Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View

NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.

    NuVasive (NUVA) Grappling with Odds: Should You Dump Stock?

    On Jun 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA), a major player in the global spine market.

      NuVasive (NUVA) at 52-Week High: What's Driving the Stock?

      Share price of NuVasive, Inc. (NUVA) scaled a new 52-week high of $81.06 on Jun 9, eventually closing a bit lower at $79.13.

        NuVasive Aims for Innovation, Global Growth amid Woes

        On May 29, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA).

          NuVasive (NUVA) Beats on Q1 Earnings, Retains 2017 View

          NuVasive, Inc. (NUVA) reported first-quarter 2017 adjusted earnings per share (EPS) of 38 cents, reflecting an 18.7% rise from the year-ago quarter.

            NuVasive (NUVA) Q1 Earnings: Disappointment in the Cards?

            Our proven model does not conclusively show that NuVasive (NUVA) is likely to beat earnings this quarter.

              NuVasive Receives FDA 510(k) Clearance in Cervical Spine

              NuVasive Inc. (NUVA) received the U.S. FDA's 510(K) clearance for one of its spine products.

                NuVasive (NUVA) Gets FDA 510(k) Clearance for CoRoent System

                Leading medical device company NuVasive, Inc. (NUVA) recently announced the receipt of U.S. FDA 510(k) clearance for its CoRoent Small Interbody System.

                  Why Is NuVasive (NUVA) Up 3.1% Since the Last Earnings Report?

                  NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    NuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017

                    NuVasive, Inc. (NUVA) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 53 cents, reflecting a 51.4% surge from the year-ago quarter.

                      Why NuVasive (NUVA) Might Surprise This Earnings Season

                      Investors are always looking for stocks that are poised to beat at earnings season and NuVasive, Inc. (NUVA) may be one such company.

                        NuVasive at 52-Week High on Preliminary Results, MHLW Nod

                        Share price of San Diego, CA-based NuVasive, Inc. (NUVA) scaled a new 52-week high of $71.03 on Jan 11, finally closing a tad lower at $70.7.

                          NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite

                          NuVasive (NUVA) recently announced the receipt of approval from MHLW, for instruments used in the eXtreme Lateral Interbody Fusion (XLIF) procedure.

                            NuVasive: Q3 Results Lack Shine, Spine Market Holds Promise

                            On Nov 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA).

                              Indradip Ghosh headshot

                              New Strong Buy Stocks for September 12th

                              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                                3 MedTech Stocks Poised to Trump Earnings in Q3

                                Positive demographic trends, new product cycles, expansion into emerging markets and widespread consolidation are the key traits for the MedTech sector.

                                  Kevin Matras headshot

                                  How to Uncover Institutional Buying

                                  Kevin Matras goes over how to screen for weekly volume increases to uncover institutional buying. Highlighted stocks include CMG, CHE, NUVA, LION and OC.

                                    David Bartosiak headshot

                                    The 5 Best Stocks to Buy in This Market

                                    A choppy market still rewards stocks that are making new highs

                                      Brian Bolan headshot

                                      Nuvasive and NeoPhotonics in the Spotlight

                                      NUVA and NPTN are profiled as aggressive growth stocks.